European Companies Search Engine

EU funding (€6,715,625): HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS Hor 31 May 2020 EU Research and Innovation programme "Horizon"

Overview

Text

HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS

Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are extremely complex, and advances in patient diagnosis and therapies slow due to the low number of patients per centre. Thus, there is a need to harmonise, store, and analyse the current HM information to speed-up and support the decision-making process for patients’ access to new therapies. HARMONY PLUS takes advantage of the capabilities of the HARMONY Big Data platform to match these unmet needs by expanding its scope to incorporate myeloproliferative neoplasms, including chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; and lymphoproliferative disorders, including Hodgkin’s lymphoma, Waldenström macroglobulinemia and all the other rare HMs not covered by HARMONY Project. In parallel, HARMONY PLUS will continue to refine and define the Core Outcome Sets (COS), especially for these new HMs to ensure the use by researchers of useful common outcomes relevant to all stakeholders. As previously accomplished in HARMONY, HARMONY PLUS is committed to pursue the maximum ethical and legal requirements, particularly to ensure patient’s right to privacy. Data-driven research within Europe will be enhanced by converting the current HARMONY platform into an Integrated Services Platform to serve as a valuable tool to support clinical trial design and use of available data as a control arm. This platform, combined with a HaemoDatabank repository with information about HMs patient biological samples across Europe, will facilitate a more efficient research and clinical trial design, and consequently will promote collaborations with recognised databases outside Europe. From the regulatory point of view, HARMONY PLUS will be a valuable technology tool during the evaluation of new treatments and drugs by also considering the patients’ needs.


Funded Companies:

Company name Funding amount
Abbvie Inc. €0.00
Agencia Espanola de Medicamentos y Productos Sanitarios €75,750
Alma Mater Studiorum - Universita Di Bologna €339,000
Bayer AG €0.00
Bundesinstitut FUR Arzneimittel UND Medizinprodukte €11,250.00
Celgene Management Sàrl €0.00
Charite - Universitaetsmedizin Berlin €335,250
Erasmus Universitair Medisch Centrum Rotterdam €90,000
European Hematology Association €664,250
European Research Initiative ON CLL e. V. €90,000
European Society FOR Blood AND Marrow Transplantation €121,250
Fondazione Italiana Sindromi Mielodisplastiche ETS €90,000
Fundacio Institut de Recerca Contra La Leucemia Josep Carreras €90,000
Fundacion Instituto de Estudios de Ciencias de La Salud de Castilla y Leon €1,606,368
Fundacion para La Investigacion del Hospital Universitario La Fe de La Comunidad Valenciana €405,000
Genome Research Ltd. LBG €54,000
GMV Soluciones Globales Internet SA €502,500
Gpoh Gemeinnutzige GmbH €90,000
Groupe Francophone des Myelodysplasies €90,000
Helsingin Yliopisto €54,000
Istituto Nazionale Di Fisica Nucleare €0.00
Janssen Pharmaceutica N.V. €0.00
Leukanet e. V. €276,125
Ludwig-Maximilians-Universitaet Muenchen €90,000
Lysarc €0.00
Masarykova Univerzita €54,000
Medisapiens Oy €32,632
Menarini Ricerche S.p.A. €0.00
MLL Munchner Leukamielabor GmbH €54,000
National Institute for Health and Care Excellence €328,500
Novartis Pharma AG €0.00
Ospedale Pediatrico Bambino Gesu €90,000
Pfizer Ltd. €0.00
Stichting Amsterdam UMC €90,000
Stiftung ELN Foundation €90,000
Synapse Research Management Partners SL €307,750
The Chancellor Masters and Scholars of the University of Cambridge €90,000
THE Lymphoma Study Association €90,000
Universidad de Navarra €90,000
Universita Degli Studi Di Torino €90,000
Universitaet ULM €90,000
University of Newcastle Upon Tyne €90,000
VIB VZW €54,000

Source: https://cordis.europa.eu/project/id/945406

The filing refers to a past date, and does not necessarily reflect the current state.